참고문헌 (10)

1. Kang, Mee Joo, Won, Young-Joo, Lee, Jae Jun, Jung, Kyu-Won, Kim, Hye-Jin, Kong, Hyun-Joo, Im, Jeong-Soo, Seo, Hong Gwan. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019. Cancer research and treatment : official journal of Korean Cancer Association, vol.54, no.2, 330-344.

   상세보기

2. Kato, Ken, Cho, Byoung Chul, Takahashi, Masanobu, Okada, Morihito, Lin, Chen-Yuan, Chin, Keisho, Kadowaki, Shigenori, Ahn, Myung-Ju, Hamamoto, Yasuo, Doki, Yuichiro, Yen, Chueh-Chuan, Kubota, Yutaro, Kim, Sung-Bae, Hsu, Chih-Hung, Holtved, Eva, Xynos, Ioannis, Kodani, Mamoru, Kitagawa, Yuko. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology, vol.20, no.11, 1506-1517.

   상세보기

3. Shah, Manish A., Kojima, Takashi, Hochhauser, Daniel, Enzinger, Peter, Raimbourg, Judith, Hollebecque, Antoine, Lordick, Florian, Kim, Sung-Bae, Tajika, Masahiro, Kim, Heung Tae, Lockhart, A. Craig, Arkenau, Hendrik-Tobias, El-Hajbi, Farid, Gupta, Mukul, Pfeiffer, Per, Liu, Qi, Lunceford, Jared, Kang, S. Peter, Bhagia, Pooja, Kato, Ken. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus : The Phase 2 KEYNOTE-180 Study. JAMA oncology, vol.5, no.4, 546-.

   상세보기

4. Kojima, Takashi, Shah, Manish A., Muro, Kei, Francois, Eric, Adenis, Antoine, Hsu, Chih-Hung, Doi, Toshihiko, Moriwaki, Toshikazu, Kim, Sung-Bae, Lee, Se-Hoon, Bennouna, Jaafar, Kato, Ken, Shen, Lin, Enzinger, Peter, Qin, Shu-Kui, Ferreira, Paula, Chen, Jia, Girotto, Gustavo, de la Fouchardiere, Christelle, Senellart, Helene, Al-Rajabi, Raed, Lordick, Florian, Wang, Ruixue, Suryawanshi, Shailaja, Bhagia, Pooja, Kang, S. Peter, Metges, Jean-Philippe. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.38, no.35, 4138-4148.

   상세보기

5. Sun, Jong-Mu, Shen, Lin, Shah, Manish A, Enzinger, Peter, Adenis, Antoine, Doi, Toshihiko, Kojima, Takashi, Metges, Jean-Philippe, Li, Zhigang, Kim, Sung-Bae, Cho, Byoung Chul, Mansoor, Wasat, Li, Shau-Hsuan, Sunpaweravong, Patrapim, Maqueda, Maria Alsina, Goekkurt, Eray, Hara, Hiroki, Antunes, Luis, Fountzilas, Christos, Tsuji, Akihito, Oliden, Victor Castro, Liu, Qi, Shah, Sukrut, Bhagia, Pooja, Kato, Ken. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. The Lancet, vol.398, no.10302, 759-771.

   상세보기

6. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F.S., Schachter, J., Pavlick, A.C., Lewis, K.D., Cranmer, L.D., Blank, C.U., O'Day, S.J., Ascierto, P.A., Salama, A.K.S., Margolin, K.A., Loquai, C., Eigentler, T.K., Gangadhar, T.C., Carlino, M.S., Agarwala, S.S., Moschos, S.J., Sosman, J.A., Goldinger, S.M., Shapira-Frommer, R., Gonzalez, R., Kirkwood, J.M., Wolchok, J.D., Eggermont, A., Li, X.N., Zhou, W., Zernhelt, A.M., Lis, J., Ebbinghaus, S., Kang, S.P., Daud, A.. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology, vol.16, no.8, 908-918.

   상세보기

7. Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V., Muro, Kei, Fuchs, Charles S., Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I., Borg, Christophe, Doi, Toshihiko, Yoon, Harry H., Savage, Mary J., Wang, Jiangdian, Dalal, Rita P., Shah, Sukrut, Wainberg, Zev A., Chung, Hyun Cheol. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol.22, no.4, 828-837.

   상세보기

8. 10.3410/f.732851580.793549623 

   

9. Pacheco, Jose M., Camidge, D. Ross, Doebele, Robert C., Schenk, Erin. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. Frontiers in oncology, vol.9, 195-.

   상세보기

10. Zhao, Joseph J., Yap, Dominic Wei Ting, Chan, Yiong Huak, Tan, Benjamin Kye Jyn, Teo, Chong Boon, Syn, Nicholas L., Smyth, Elizabeth C., Soon, Yu Yang, Sundar, Raghav. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.40, no.4, 392-402.

    상세보기